Yves Albert DeClerck

List of Publications by Citations

87 papers	6,068 citations	45 h-index	77 g-index
95 ext. papers	6,917 ext. citations	8 avg, IF	5.76 L-index

#	Paper	IF	Citations
87	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. *Cell*, **2020**, 182, 1044-1061.e18	36.2	288
86	Interleukin-6 in bone metastasis and cancer progression. *European Journal of Cancer*, **2010**, 46, 1223-31	7.5	265
85	Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. *Cancer and Metastasis Reviews*, **2010**, 29, 249-61	9.6	264
84	Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). *Journal of Biological Chemistry*, **1998**, 273, 1216-22	5.4	235
83	Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. *Journal of Clinical Investigation*, **2009**, 119, 1524-36	15.9	215
82	Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. *Cancer Research*, **2013**, 73, 4965-77	10.1	191
81	Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. *Cancer Research*, **2004**, 64, 1675-86	10.1	187
80	Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. *Cancer and Metastasis Reviews*, **2006**, 25, 35-43	9.6	180
79	Proteases, extracellular matrix, and cancer: a workshop of the path B study section. *American Journal of Pathology*, **2004**, 164, 1131-9	5.8	179
78	Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 10026-31	11.5	141
77	Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. *Cancer Research*, **2009**, 69, 329-37	10.1	139
76	The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. *Cancer Research*, **2005**, 65, 3200-8	10.1	137
75	TGF-beta3-induced palatogenesis requires matrix metalloproteinases. *Molecular Biology of the Cell*, **2001**, 12, 1457-66	3.5	137
74	Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases. *European Journal of Cancer*, **2006**, 42, 310-8	7.5	112
73	Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. *Cancer Cell*, **2008**, 14, 324-34	24.3	107
72	Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 rgulates pro-MMP-2 activation. *Journal of Biological Chemistry*, **2004**, 279, 8592-601	5.4	107
71	Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. *Apmis*, **1999**, 107, 111-9	3.4	105

70	Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2. *Journal of Biological Chemistry*, **2000**, 275, 41415-23	5.4	104
69	Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma. *Cancer Research*, **2013**, 73, 3852-64	10.1	96
68	Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing. *Cancer Research*, **2015**, 75, 2969-74	10.1	93
67	The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. *Cancer Research*, **2004**, 64, 2328-32	10.1	92
66	Proteases and protease inhibitors in tumor progression. *Advances in Experimental Medicine and Biology*, **1997**, 425, 89-97	3.6	92
65	Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. *Cancer Research*, **2017**, 77, 5142-5157	10.1	89
64	Structure and characterization of the human tissue inhibitor of metalloproteinases-2 gene. *Journal of Biological Chemistry*, **1996**, 271, 25498-505	5.4	86
63	Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression. *Enzyme & Protein*, **1996**, 49, 72-84		81
62	Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. *Journal of Clinical Investigation*, **2007**, 117, 2702-12	15.9	75
61	Tissue inhibitors of matrix metalloproteinases in cancer. *Annals of the New York Academy of Sciences*, **1999**, 878, 108-19	6.5	72
60	A fatal case of inappropriate ADH secretion induced by cyclophosphamide therapy. *Cancer*, **1979**, 44, 896-8	6.4	69
59	Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. *Cancer Research*, **2005**, 65, 1129-35	10.1	66
58	Identification of the tissue inhibitor of metalloproteinases-2 (TIMP-2) binding site on the hemopexin carboxyl domain of human gelatinase A by site-directed mutagenesis. The hierarchical role in binding TIMP-2 of the unique cationic clusters of hemopexin modules III and IV. *Journal of Biological Chemistry*, **1999**, 274, 4421-9	5.4	66
57	Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. *Journal of the National Cancer Institute*, **2012**, 104, 1470-84	9.7	65
56	Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by fibrillar collagen. *Journal of Biological Chemistry*, **2005**, 280, 40187-94	5.4	63
55	Mechanisms of invasion and metastasis in human neuroblastoma. *Cancer and Metastasis Reviews*, **2006**, 25, 645-57	9.6	62
54	A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma. *Cancer Research*, **2012**, 72, 2228-38	10.1	57
53	Computerized quantification of tissue vascularization using high-resolution slide scanning of whole tumor sections. *Journal of Histochemistry and Cytochemistry*, **2003**, 51, 151-8	3.4	55

52	Bone marrow-derived mesenchymal stromal cells promote survival and drug resistance in tumor cells. *Molecular Cancer Therapeutics*, **2014**, 13, 962-75	6.1	52
51	Identification of galectin-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma. *Journal of Biological Chemistry*, **2008**, 283, 18573-81	5.4	52
50	Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis. *Cancer Research*, **2006**, 66, 2691-9	10.1	52
49	Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer. *Cell Reports*, **2018**, 25, 2177-2191.e7	10.6	51
48	Bone marrow microenvironment and tumor progression. *Cancer Microenvironment*, **2008**, 1, 23-35	6.1	50
47	Mechanisms of bone invasion and metastasis in human neuroblastoma. *Cancer Letters*, **2005**, 228, 203-9	9.9	49
46	The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding. *Cancer and Metastasis Reviews*, **2019**, 38, 483-492	9.6	47
45	More than the genes, the tumor microenvironment in neuroblastoma. *Cancer Letters*, **2016**, 380, 304-14	9.9	46
44	Desmoplasia: a response or a niche?. *Cancer Discovery*, **2012**, 2, 772-4	24.4	45
43	NF-Y and Sp1 cooperate for the transcriptional activation and cAMP response of human tissue inhibitor of metalloproteinases-2. *Journal of Biological Chemistry*, **2000**, 275, 18602-10	5.4	42
42	Runx2 promotes both osteoblastogenesis and novel osteoclastogenic signals in ST2 mesenchymal progenitor cells. *Osteoporosis International*, **2012**, 23, 1399-413	5.3	37
41	Purification and characterization of a collagenase inhibitor produced by bovine vascular smooth muscle cells. *Archives of Biochemistry and Biophysics*, **1988**, 265, 28-37	4.1	36
40	Contribution of neuroblastoma-derived exosomes to the production of pro-tumorigenic signals by bone marrow mesenchymal stromal cells. *Journal of Extracellular Vesicles*, **2017**, 6, 1332941	16.4	34
39	A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. *Pediatric Blood and Cancer*, **2011**, 57, 275-82	3	34
38	Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma. *Clinical Cancer Research*, **2011**, 17, 7093-104	12.9	32
37	The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. *Cancer Research*, **2007**, 67, 9346-55	10.1	32
36	Tumor-associated macrophages promote neuroblastoma via STAT3 phosphorylation and up-regulation of c-MYC. *Oncotarget*, **2017**, 8, 91516-91529	3.3	31
35	The cyclin-dependent kinase inhibitors p15INK4B and p21CIP1 are critical regulators of fibrillar collagen-induced tumor cell cycle arrest. *Journal of Biological Chemistry*, **2007**, 282, 24471-6	5.4	30

34	Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells. *Clinical Cancer Research*, **2019**, 25, 4761-4774	12.9	29
33	Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity. *PLoS ONE*, **2015**, 10, e0133786	3.7	29
32	Stromelysin-1 (MMP-3) is a target and a regulator of Wnt1-induced epithelial-mesenchymal transition (EMT). *Cancer Biology and Therapy*, **2010**, 10, 198-208	4.6	29
31	Cancer-Associated Fibroblasts: Understanding Their Heterogeneity. *Cancers*, **2020**, 12,	6.6	29
30	Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate. *Cancer Research*, **2003**, 63, 3026-31	10.1	28
29	Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells. *Journal of Cellular Physiology*, **1996**, 167, 333-40	7	27
28	Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-B signaling, and synergizes with an ERK inhibitor. *Cancer Biology and Therapy*, **2012**, 13, 349-57	4.6	26
27	Urokinase induces receptor mediated brain tumor cell migration and invasion. *Journal of Neuro-Oncology*, **1998**, 40, 215-26	4.8	26
26	Multimodal imaging analysis of tumor progression and bone resorption in a murine cancer model. *Journal of Computer Assisted Tomography*, **2006**, 30, 525-34	2.2	25
25	Gene therapy for hepatocellular carcinoma using non-viral vectors composed of bis guanidinium-tren-cholesterol and plasmids encoding the tissue inhibitors of metalloproteinases TIMP-2 and TIMP-3. *Cancer Gene Therapy*, **2003**, 10, 435-44	5.4	25
24	TIMP-2 is released as an intact molecule following binding to MT1-MMP on the cell surface. *Experimental Cell Research*, **2004**, 293, 164-74	4.2	25
23	Primary central nervous system lymphoma without intracranial mass in a child. Diagnosis by documentation of monoclonality. *Cancer*, **1985**, 56, 2804-8	6.4	25
22	Microsomal prostaglandin E synthase-1 enhances bone cancer growth and bone cancer-related pain behaviors in mice. *Life Sciences*, **2011**, 88, 693-700	6.8	22
21	Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis. *Cancer Biology and Therapy*, **2012**, 13, 534-41	4.6	21
20	Establishment of long-term in vitro cultures of human ovarian cystadenomas and LMP tumors and examination of their spectrum of expression of matrix-degrading proteinases. *Gynecologic Oncology*, **1997**, 67, 277-84	4.9	19
19	The Tumor Microenvironment in Neuroblastoma: New Players, New Mechanisms of Interaction and New Perspectives. *Cancers*, **2020**, 12,	6.6	17
18	The C-terminal domain of tissue inhibitor of metalloproteinases-2 is required for cell binding but not for antimetalloproteinase activity. *Biochemical and Biophysical Research Communications*, **1997**, 236, 100-5	3.4	14
17	Magnetic resonance imaging for the evaluation of a novel metastatic orthotopic model of human neuroblastoma in immunodeficient mice. *Clinical and Experimental Metastasis*, **2000**, 18, 455-61	4.7	14

16	Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance. *Molecular Cancer Therapeutics*, **2017**, 16, 2516-2527	6.1	11
15	Hemophilus influenzae type b infections: recurrent disease due to ampicillin-resistant strains. *Journal of Pediatrics*, **1977**, 90, 319-20	3.6	11
14	Interaction between bone marrow stromal cells and neuroblastoma cells leads to a VEGFA-mediated osteoblastogenesis. *International Journal of Cancer*, **2015**, 137, 797-809	7.5	10
13	Identification of the TIMP-2 binding site on the gelatinase A hemopexin C-domain by site-directed mutagenesis and the yeast two-hybrid system. *Annals of the New York Academy of Sciences*, **1999**, 878, 747-53	6.5	9
12	MYCN-dependent expression of sulfatase-2 regulates neuroblastoma cell survival. *Cancer Research*, **2014**, 74, 5999-6009	10.1	8
11	Les m□alloprot□ases matricielles et leurs inhibiteurs synth□iques dans la progression tumorale. *Medecine/Sciences*, **2002**, 18, 565-575		8
10	Cloning and partial structure of the gene encoding human tissue inhibitor of metalloproteinases-3. *Gene*, **1996**, 170, 287-8	3.8	7
9	Macrocytosis and pure RBC anemia caused by azathioprine. *JAMA Pediatrics*, **1980**, 134, 377-9		6
8	Fat, Calories, and Cancer. *Cancer Research*, **2016**, 76, 509-10	10.1	5
7	Paternal Risk Factors for Oral Clefts in Northern Africans, Southeast Asians, and Central Americans. *International Journal of Environmental Research and Public Health*, **2017**, 14,	4.6	5
6	Considering the critical interface between tumor cells and stromal cells in the search for targets for anticancer therapy. *Cancer Cell*, **2005**, 7, 408-9	24.3	3
5	Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment. *Journal of Visualized Experiments*, **2017**,	1.6	2
4	The Tumor Microenvironment as a Target for Therapeutic Intervention **2015**, 47-63		
3	Focus on the cell membrane: the need for dissociation and detachment in tumoral invasion. *Cancer Biology and Therapy*, **2004**, 3, 632-3	4.6	
2	Tissue Inhibitors of Metalloproteinases in Cancer **2002**, 169-194		
1	The Extracellular Matrix and the Growth and Survival of Tumors **2010**, 695-710		